Drug-drug interaction between trastuzumab emtansine (T-DM1) and orally administered tacrolimus in a patient and in rats., PMID:40513507
Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review., PMID:40493045
A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer., PMID:40484776
Treatment of breast cancer in a patient with sickle cell disease., PMID:40484435
Adverse effect of trastuzumab deruxtecan in solid tumours: a systematic review and meta-analysis., PMID:40466817
Mechanisms of resistance to antibody-drug conjugates in cancers., PMID:40460510
Radiobioconjugate of Kadcyla with Radioactive Gold Nanoparticles for Targeted Therapy of HER2-Overexpressing Cancers., PMID:40443068
Molecular imaging predicts trastuzumab-deruxtecan (T-DXd) response in head and neck cancer xenograft models., PMID:40437743
Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients., PMID:40437155
Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer., PMID:40437017
Male Occult Primary Breast Cancer Diagnosed with Small Bowel Metastases: A Case Report., PMID:40433060
Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials., PMID:40430899
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine., PMID:40428777
HER2-Positive Breast Cancer-Current Treatment Management and New Therapeutic Methods for Brain Metastasis., PMID:40426980
T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective., PMID:40405946
T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects., PMID:40402389
Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience., PMID:40380283
Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer., PMID:40374836
Cost-Utility Analysis of Trastuzumab-Emtansine Versus Trastuzumab for the Treatment of Residual Invasive HER-2-Positive Breast Cancer in Iran., PMID:40365303
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan., PMID:40349141
Successful Neoadjuvant Treatment Using Trastuzumab Emtansine (Kadcyla) for Locally Advanced and Metastatic Lacrimal Gland Adenocarcinoma., PMID:40334147
Enhanced cytotoxicity of T-DM1 in HER2-low carcinomas via autophagy inhibition., PMID:40315224
Navigating antibody‒drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies., PMID:40304863
The mechanisms of HER2 targeted ADCs are dependent on Rab GTPases., PMID:40297622
Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan., PMID:40295416
Versatile intact LC-MS method for evaluating the drug-antibody ratio and drug load distribution of antibody-drug conjugates in human plasma., PMID:40267607
Therapy of early breast cancer: current status and perspectives., PMID:40261372
Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer: A Retrospective Study., PMID:40255472
Response to Michelerio et al regarding "Antibody-drug conjugates: A review of cutaneous adverse effects"., PMID:40239815
Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing., PMID:40201309
Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: an observational cohort study., PMID:40192324
Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study., PMID:40166653
CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance., PMID:40165206
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study., PMID:40162996
Real-Life Experience of HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Advanced Breast Cancer Patients Treated With T-DXd (Trastuzumab Deruxtecan): A Multicentric Portuguese Study., PMID:40161117
Microfluidic organoid-slice-on-a-chip system for studying anti-cholangiocarcinoma drug efficacy and hepatorenal toxicity., PMID:40152597
Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy., PMID:40148195
Effects of trastuzumab emtansine on canine osteosarcoma cells., PMID:40128930
Antibody-drug conjugates in breast cancer: current evidence and future directions., PMID:40114224
Stability of intravenous antibody dilutions in clinical use: Differences across patient populations with varying body weights., PMID:40112902
New treatment options for generalized HER2-positive breast cancer in higher-line systemic palliative therapy., PMID:40088439
Postmarketing Assessment of Antibody-Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach., PMID:40040312
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP)., PMID:40036771
Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database., PMID:40033454
Is ADC a rising star in solid tumor? An umbrella review of systematic reviews and meta-analyses., PMID:40021960
Antibody-drug conjugates in elderly patients with breast cancer., PMID:40020509
Optimal follow-up duration of cardiac function tests in patients treated with trastuzumab: an analysis using the Japanese Adverse Drug Event Report (JADER) database., PMID:40009314
[Three Cases of HER2-Positive Breast Cancer Brain Metastases That Responded to T-DXd after Whole-Brain Radiation Therapy and Subsequent Tumor Regrowth]., PMID:39948915
Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis., PMID:39943891
Monoclonal Antibodies and Small-Molecule Inhibitors Associated Osteonecrosis of Jaw: A Retrospective Pharmacovigilance Study., PMID:39922223
For research use only. Not for human or drug use.
